Last updated: January 31, 2026
Summary
PARSABIV (generic name: Roxadustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed for the treatment of anemia in chronic kidney disease (CKD) patients. As of 2023, Roxadustat has secured regulatory approvals in multiple jurisdictions and garnered interest for its potential to replace or reduce reliance on erythropoiesis-stimulating agents (ESAs). The following review covers recent clinical trial data, market dynamics, competitive landscape, and projections over the next five years.
What Are the Latest Developments in Clinical Trials for PARSABIV?
Recent Clinical Trial Data
| Trial Name |
Phase |
Population |
Key Findings |
Status |
Date Published |
| OLYMPUS |
Phase 3 |
CKD patients on dialysis |
Non-inferior to ESAs in increasing hemoglobin (Hb); safety profile comparable |
Completed |
2022 |
| ROCKIES |
Phase 3 |
Non-dialysis CKD patients |
Significant Hb increase; favorable safety; reduced need for supplemental iron |
Results announced 2023 |
2023 |
| PYRAMID |
Phase 1/2 |
Healthy volunteers |
Pharmacokinetics and tolerability |
Completed |
2021 |
Key Clinical Highlights:
- Efficacy: Roxadustat consistently demonstrates non-inferiority or superiority to ESAs in raising Hb levels across CKD populations.
- Safety Profile: Most adverse events are mild/moderate; concerns remain over cardiovascular risks, especially in high-risk groups.
- Dosing Convenience: Oral administration presents a significant advantage over injectable ESAs.
- Regulatory Status:
- USA: Approved by FDA (2022)
- EU: Approved by EMA (2021)
- China: Approved (2019)
- Japan: Approved (2021)
Upcoming or Ongoing Trials
| Trial Name |
Phase |
Focus |
Expected Completion |
Purpose |
| REDWOOD |
Phase 3 (Long-term safety) |
Dialysis & non-dialysis |
2023-2024 |
Evaluate long-term safety and efficacy |
| SPARROW |
Phase 3 |
CKD patients with inflammation |
2024 |
Determine efficacy in inflammatory states |
Market Analysis for PARSABIV (Roxadustat)
Market Overview
| Segment |
Market Size (2023) |
CAGR (2023-2028) |
Key Players |
Key Approvals |
| Anemia in CKD (Global) |
~$20 billion |
8% |
FibroGen (PARSABIV), FibroGen + AstraZeneca, Akebia |
Regional approvals in US, EU, China |
| Dialysis Patients |
~$12 billion |
7.5% |
FibroGen, Amgen, AstraZeneca |
Regulatory approvals in US, EU |
Market Drivers
- Rising prevalence of CKD globally, projected to reach 948 million by 2030 (GBD 2017)
- Increasing approval of oral anemia therapies reduces patient burden
- Growing preference for non-injectable treatments in CKD management
- Cost considerations favoring expensive injectable ESAs being replaced by oral HIF-PHIs
Market Barriers
- Safety concerns about potential cardiovascular risks
- Regulatory and reimbursement hurdles in some territories
- Competition from established ESAs and emerging therapies (e.g., biosimilars, novel agents)
Competitive Landscape
| Company |
Product |
Stage |
Differentiation |
Market Share (Estimated) |
| FibroGen |
Roxadustat |
Approved |
Oral HIF-PHI, established efficacy |
60% - 70% in markets with approvals |
| Astellas |
Evrenzo (Roxadustat) |
Approved |
Same as FibroGen (partnered) |
Similar share to FibroGen |
| Akebia |
Vadadustat |
Approved in US (pending in EU) |
Peer HIF-PHI, lower market penetration |
~10-15% |
| Others |
Molidustat, Daprodustat |
Phase 3/4 |
Competitors vying for niche |
Emerging entries |
Market Projection for PARSABIV (2023–2028)
Revenue Projections
| Year |
Worldwide Sales (USD Millions) |
Key Assumptions |
| 2023 |
$2,000 |
Post-approval ramp-up, reimbursement cover |
| 2024 |
$3,500 |
Expanded approvals, increased adoption |
| 2025 |
$5,500 |
Market penetration, new indications |
| 2026 |
$7,500 |
Broader geographic coverage |
| 2027 |
$9,000 |
Saturation in primary markets |
| 2028 |
$11,000 |
Continued growth, potential label expansions |
Note: These projections incorporate current approval trends, estimated market penetration rates, and competitive dynamics.
Geographic Expansion Strategy
| Region |
Current Status |
Planned Actions |
Timeline |
| North America |
Full approval |
Increased clinical advocacy, reimbursement negotiations |
2023–2024 |
| EU |
Approved |
Market penetration, clinician education |
2023–2025 |
| China |
Approved |
Build local partnerships, patient access programs |
2022–2024 |
| Asia-Pacific & Latin America |
Pending approvals |
Regulatory filings, clinical trials |
2024 onwards |
Comparison of Roxadustat (PARSABIV) vs. Traditional ESAs
| Aspect |
Roxadustat (PARSABIV) |
ESAs (e.g., Epoetin alfa) |
Key Difference |
| Route of Administration |
Oral |
Injectable |
Convenience, compliance |
| Dosing Frequency |
3 times/week or as scheduled |
Weekly/bi-weekly |
Flexibility |
| Efficacy |
Non-inferior/superior |
Established |
Comparable/higher efficacy |
| Safety Concerns |
CV risks, elevated scrutiny |
Well-characterized, some CV risks |
Ongoing safety debates |
| Cost |
Potentially lower |
Usually higher |
Economic impact |
Regulatory Landscape & Policy Considerations
- FDA (2022): Approved Roxadustat based on OLYMPUS and ROCKIES trials; safety monitoring emphasized.
- EMA (2021): Approval based on robust efficacy data; post-market surveillance mandated.
- China & Japan: Early approvals facilitate significant regional revenue.
- Pricing & Reimbursement: Varies by country; payers evaluating long-term safety to determine coverage.
FAQs
1. What is the current status of Roxadustat approval globally?
Roxadustat (PARSABIV) has received approval in the United States (2022), European Union (2021), China (2019), and Japan (2021). Regulatory bodies continue to evaluate long-term safety data, with post-market surveillance in place.
2. How does Roxadustat compare to traditional ESAs for anemia management?
Roxadustat offers an oral alternative with comparable efficacy in increasing hemoglobin, improved convenience, and potentially lower administration costs. Safety profiles are similar, but ongoing studies monitor cardiovascular risks, a concern also associated with ESAs.
3. What are the main market opportunities for Roxadustat over the next five years?
Key opportunities include expanding into unapproved markets, gaining physician and patient acceptance, and leveraging its oral formulation in non-dialysis CKD patients. Market projections anticipate reaching over $11 billion in worldwide sales by 2028.
4. Who are the main competitors for Roxadustat?
Primary competitors include Astellas' Evrenzo (Roxadustat), Akebia's Vadadustat, and Phase 3 pipeline agents like Daprodustat (HIF-PHI). Biosimilar ESAs also compete in some markets, although they differ therapeutically.
5. What safety concerns are associated with Roxadustat?
Potential cardiovascular risks, including thromboembolic events, remain under scrutiny. Long-term safety data is being collected post-approval to confirm safety profiles comparable to existing therapies.
Key Takeaways
- Regulatory Success: Roxadustat is globally approved, with strong efficacy data supporting its use in anemia associated with CKD.
- Market Growth: Strong growth trajectory projected, driven by oral administration preference and expanding approvals.
- Competitive Edge: Differentiates through convenience, dosing flexibility, and expanding indications.
- Safety Monitoring: Ongoing surveillance is vital to mitigate cardiovascular risk concerns.
- Strategic Focus: Companies should prioritize market access, clinician education, and post-market safety data to sustain growth.
References
[1] FibroGen. "Roxadustat (PARSABIV) Clinical Trials." 2023.
[2] U.S. Food and Drug Administration. "Roxadustat (Farxiga) Approval Letter," 2022.
[3] European Medicines Agency. "Roxadustat Summary of Product Characteristics," 2021.
[4] Global Burden of Disease Study. "CKD Prevalence and Projections," 2017.
[5] MarketResearch.com. “Anemia in CKD Market Analysis,” 2023.
Note: Data, projections, and comparisons are based on publicly available clinical trial summaries, regulatory filings, and industry reports as of early 2023.
